APCINTEX LIMITED
APCINTEX LIMITED is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at APCINTEX LIMITED.
APCINTEX LIMITED is a company.
Key people at APCINTEX LIMITED.
ApcinteX Limited is a UK-based biotechnology company focused on research and experimental development in biotechnology, specifically advancing therapies targeting mutated alpha-1 antitrypsin and protein C inhibitors for conditions like hemophilia A.[1][2][4] Incorporated as a private limited company, it operates as a micro-entity with under 10 employees, serving the biotech and pharmaceutical sectors by developing novel haemostatic agents to address unmet needs in blood clotting disorders.[1][2] As of its latest accounts to 31 December 2023, the company holds £24.15M in total assets and £8.35M in net assets, with £2.95M in cash, reflecting a stable but debt-leveraged position (65% debt ratio).[2] Its work contributes to the startup biotech ecosystem through innovative drug pipelines, though growth momentum appears steady rather than explosive, marked by ongoing clinical trials and recent charge satisfactions.[2][4]
ApcinteX Limited was incorporated on 16 June 2014 as SERPIN HAEMOSTATICS LIMITED, initially focused on serpin-based haemostatics, before rebranding to ApcinteX Limited on 2 April 2016 to reflect its pivot toward advanced biotech inhibitors.[1][2] The company emerged from research into haemostatic technologies, with key officers including at least five individuals and shareholders driving its evolution from early-stage biotech to a firm with clinical-stage assets.[2] Pivotal moments include building a drug pipeline with mutated alpha-1 antitrypsin targeting protein C for hemophilia A (now discontinued in highest phase) and recent clinical trial initiations in 2023 and 2024, alongside financial growth to multi-million assets.[2][4] Its registered office moved to 3rd Floor, 1 Ashley Road, Altrincham, Cheshire in 2022, signaling operational maturity.[1][2]
ApcinteX rides the wave of precision biotech targeting rare blood disorders like hemophilia A, where protein C inhibitors address unmet needs in clotting factor therapies amid a global push for gene- and protein-based haemostatics.[4] Timing aligns with surging investment in UK biotech post-2014 (its founding era), fueled by R&D tax credits and ecosystem hubs like Altrincham/Manchester, amplifying small firms' impact.[1][2] Market forces favoring it include rising demand for next-gen anticoagulants/antidotes and clinical trial momentum, despite a discontinued lead asset—its asset base provides runway amid biotech funding winters.[2][4] It influences the ecosystem by contributing to consolidated platforms, as seen in parallels with multi-biotech mergers like Centessa Pharmaceuticals, fostering specialized innovation in a fragmented field.[3]
ApcinteX is poised for pipeline advancement, with 2024 trial starts signaling potential Phase progression beyond discontinued hemophilia efforts, leveraging £24M+ assets for biotech partnerships or acquisitions.[2][4] Trends like AI-driven protein engineering and hemophilia market expansion (projected to grow with novel modalities) will shape its path, potentially elevating its micro status if trials yield data by 2026 filings.[1][2] Influence may evolve through M&A, mirroring sector consolidations, transforming it from niche R&D player to broader haemostatics contributor—watch next accounts for momentum signals tying back to its serpin roots.[2][3][4]
Key people at APCINTEX LIMITED.
